Abstract: Aerosolization of therapeutic proteins is demonstrated using recombinant .alpha..sub.1 -antitrypsin for treatment of emphysema as paradigmatic.

Abstract: Blood clotting function assays are improved by the use of a colloidal silica contact activator made by the process comprising (a) contacting an alkali silicate solution with an ion-exchange material for removing alkali metal ions from the silicate solution, and (b) recovering the colloidally dispersed particles from the ion exchange material.

Abstract: An ophthalmic aqueous solution having an ionic salt ion content within the range 0.01% to 7.5% expressed as sodium chloride equivalents and comprising a non-ionic synthetic polymer such as polyvinyl alcohol and/or polyethylene glycol, and a non-ionic tonicity adjusting agent. The solution is effective in treating "dry eye" conditions by causing a normalization of irregularly structured tears and at least retarding the precipitation of potein-like substances from the aqueous layers thereof.

Abstract: A lens case for an intraocular lens includes a base carrying a receptacle for a lens holder and a soaking tray.

Abstract: A diagnostic means and method of testing for pregnancy in humans and a test kit incorporating such diagnostic means and ancillary materials. A sample of a patient's first morning urine is added to a test tube containing a known lyophilized reagent. The tube is capped, shaken to mix the contents, and placed upright for one to two hours. The tube is then inverted and compared with positive and negative standard vials to show either agglutination of particles, such as red blood cells, contained therein, in which case the subject is not pregnant, or a failure to agglutinate, in which event the patient is pregnant. The test tube is of sufficient dimension to support capillary action and is formed from, or has its interior surface coated with, a material which is non-wettable to the liquid contained therein.

Abstract: A method for treating red eye by administering to the afflicted eye a composition comprising an anti-inflammatory amount of an antagonist for H.sub.2 receptors in the eye, preferably cimetidine, and a non-toxic, pharmaceutically acceptable, ophthalmological carrier.

Abstract: A process is disclosed for preparing substituted bis-(amidinoureas) by reacting a 1-substituted-4-alkyl-4-isothiobiuret with a compound containing two aliphatic amino groups.

Abstract: Pharmaceutical vehicles for delivery of pharmacologically active chemical materials to mucous membranes, as well as pharmaceutically active compositions containing such vehicles, are provided. The pharmaceutical vehicles are clear, water-miscible, physiologically-acceptable, liquid compositions which gel to a thickened, non-flowing and adhering consistency at human body temperature. They are liquid at ambient room temperature and have a gel transition temperature in the range of from about 25.degree. C. to about 40.degree. C. Aqueous solutions of certain polyoxyethylene-polyoxypropylene condensates are suitable vehicles. Also provided are pharmaceutical compositions containing added pharmacologically active chemical material, i.e., a drug or medicament. A method of delivering the drug or medicament to a mucous membrane is also provided.This is a continuation of application Ser. No. 661,612, filed Feb. 26, 1976, now U.S. Pat. No. 4,100,271.

Abstract: Novel N,N'-bis(phenylcarbamoylalkyl)amidines having antiarrhythmic activity are disclosed. They are prepared by reacting an aminoalkanoylanilide with an active acid derivative such as an imidic acid ester or an alkyl orthoester.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Zwherein B is carbamylguanidino or thiocarbamylguanidino; Y is an alkylene group which contains one to three nitrogen atoms or which contains two nitrogens as part of a cyclic structure; and Z can represent a number of groups such as alkyl, cycloalkyl, aryl and aralkyl.

Abstract: Antimicrobial compounds are disclosed having the formulaZ--B--Y--B--Zwherein B is carbamylguanidino or thiocarbamylguanidino; Y is a bivalent hydrocarbon radical which can be aliphatic, alicyclic or aromatic or a combination of aliphatic with alicyclic or aromatic; and Z can represent a number of groups such as alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkylthioalkyl or phenylthioalkyl.

Abstract: Cardiac arrhythmias can be treated by administering an effective amount of 3-aryloxy-1-(2-or 4-iminodihydro-1-pyridyl)-2-propanol or phamaceutically acceptable acid addition compound. Many new effective compounds of this type are disclosed.

Abstract: An ophthalmic solution is disclosed comprising an aqueous solution of polyvinyl alcohol, hydroxyethyl cellulose, polyvinylpyrrolidone, and, optionally, hydroxypropyl methylcellulose. The ophthalmic solution is used in treating dry eye syndrome due to insufficient tear production in humans and mammals, and as an ocular lubricant for inflamed eyes.

Abstract: Bronchial asthma and other bronchospastic and allergic diseases are treated by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = C.sub.1 -C.sub.3 alkyl,R.sub.3 = c.sub.1 -c.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl, C.sub.3 -C.sub.7 alkynyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.4 -C.sub.7 cycloalkylalkyl,R.sub.8 = h, c.sub.1 -c.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl or C.sub.3 -C.sub.4 cycloalkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.3 alkyl, or phenylNovel and preferred bronchodilator and antiallergy compounds are disclosed having the formula ##STR2## wherein: R.sub.1 = C.sub.1 -C.sub.2 alkylR.sub.3 = ch.sub.2 --(c.sub.3 -c.sub.4 alkyl),--CH.sub.2 --(C.sub.3 -C.sub.4 alkenyl), or --CH.sub.2 --(C.sub.3 -C.sub.4 cycloalkyl)R.sub.8 = h, c.sub.1 -c.sub.2 alkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B --Z .sup.. nHAwherein B is carbamylguanidino, or thiocarbamylguanidino, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkylthio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; phenoxy C.sub.2 -C.sub.6 alkyl; phenylthio C.sub.2 -C.sub.6 alkyl; C.sub.6 -C.sub.14 aryl; C.sub.7 -C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Z .nHAwherein B is carbamylguanidino, or thiocarbamylguanidino, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consistng of C.sub.1 -C.sub.2 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkythio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; phenoxy C.sub.2 -C.sub.6 alkyl; phenylthio C.sub.2 -C.sub.6 alkyl; C.sub.6 -C.sub.14 aryl; C.sub.7 -C.sub.14 aralkyl and arylcycloalkyl; and C.sub.